Modality
ASO
MOA
VEGFi
Target
GIP-R
Pathway
Checkpoint
MelanomaRBOvarian Ca
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
~Feb 2018
→ ~May 2019
Phase 2
~Aug 2019
→ ~Nov 2020
Phase 3
Feb 2021
→ Dec 2031
Phase 3Current
NCT05870469
204 pts·RB
2021-02→2028-10·Active
NCT07854273
1,511 pts·RB
2023-01→2026-01·Not yet recruiting
NCT05894996
2,606 pts·RB
2023-06→2026-10·Recruiting
+1 more trial
4,461 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2026-01-242mo agoPh3 Readout· RB
2026-10-116mo awayPh3 Readout· RB
2028-10-182.6y awayPh3 Readout· RB
2031-12-135.7y awayPh3 Readout· Melanoma
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Active
P3
Recruit…
P3
Not yet…
P3
Recruit…
Catalysts
Ph3 Readout
2026-01-24 · 2mo ago
RB
Ph3 Readout
2026-10-11 · 6mo away
RB
Ph3 Readout
2028-10-18 · 2.6y away
RB
Ph3 Readout
2031-12-13 · 5.7y away
Melanoma
RecruitingActiveNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05870469 | Phase 3 | RB | Active | 204 | Mayo |
| NCT07854273 | Phase 3 | RB | Not yet recr... | 1511 | NT-proBNP |
| NCT05894996 | Phase 3 | RB | Recruiting | 2606 | HbA1c |
| NCT07543876 | Phase 3 | Melanoma | Recruiting | 140 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa |